An antifibrinolytic is a type of drug that slows or stops the breakdown of blood clots, helping your body hold onto the clots it has already formed. These medications are used in surgery, trauma care, heavy menstrual bleeding, and dental procedures to reduce blood loss. The two most widely used antifibrinolytics are tranexamic acid and aminocaproic acid, both available in oral, injectable, and topical forms.
How Antifibrinolytics Work
When you bleed, your body builds a clot from a mesh of fibrin fibers. Once the injury starts healing, your body naturally dissolves that clot through a process called fibrinolysis. An enzyme called plasmin does the dissolving, and it’s created when a precursor molecule, plasminogen, gets activated on the surface of the clot.
Antifibrinolytics interrupt this process. Tranexamic acid and aminocaproic acid are both synthetic amino acids that mimic lysine, a protein building block. They work by latching onto specific binding sites on plasminogen, physically blocking it from attaching to the fibrin clot. If plasminogen can’t dock onto the clot, it never gets activated into plasmin, and the clot stays intact longer.
A third antifibrinolytic, aprotinin, works differently. Instead of blocking activation, it plugs directly into the active site of plasmin itself, preventing it from cutting through fibrin. Aprotinin was pulled from routine clinical use due to safety concerns but remains available in limited settings.
Common Medical Uses
The broadest use of antifibrinolytics is in surgery. In cardiac surgery involving a heart-lung bypass machine, giving an antifibrinolytic before the procedure begins can significantly cut the need for blood transfusions. A large Cochrane review found that tranexamic acid reduced the likelihood of needing a red blood cell transfusion by 39% compared to no treatment. Aminocaproic acid reduced it by 19%. These drugs are also standard in major orthopedic procedures like total knee and hip replacements, as well as spinal and liver surgery.
In trauma, timing matters enormously. The CRASH-2 trial, which enrolled over 20,000 bleeding trauma patients across 40 countries, found that tranexamic acid given within eight hours of injury reduced death from bleeding by 15% and overall mortality by 9%. Patients treated sooner after injury saw even larger benefits. Tranexamic acid is now part of trauma protocols worldwide.
Heavy menstrual bleeding is one of the most common non-surgical uses. The recommended oral dose is about 1 gram taken three times daily for up to four or five days, starting on the first day of the period, with a maximum of 4 grams per day. This approach consistently reduces menstrual blood loss and is a first-line option for people who want a non-hormonal treatment.
Dental Procedures and Bleeding Disorders
People with hemophilia or von Willebrand disease face particular risks during dental extractions. Antifibrinolytics can be given as a mouthwash, typically a 5% tranexamic acid solution, swished for two minutes four times daily for seven days after the procedure. This topical approach delivers the drug directly to the surgical site, helping stabilize clots in the mouth where saliva and chewing constantly challenge healing tissue.
How the Body Processes These Drugs
Tranexamic acid has a relatively short working life in the body. After an intravenous dose, it clears through three phases, with a final elimination half-life of about two hours. More than 95% of the drug leaves the body unchanged through the kidneys within 24 hours. Because the kidneys do nearly all the work of clearing it, people with significant kidney problems may need adjusted dosing or closer monitoring.
Aminocaproic acid follows a similar path, also cleared primarily through the kidneys. Both drugs are available as oral tablets, liquid solutions, and intravenous formulations, giving clinicians flexibility depending on the situation.
Side Effects and Safety
The most important concern people raise about antifibrinolytics is whether preventing clot breakdown could cause dangerous clots elsewhere. A large systematic review and meta-analysis found no overall increase in blood clots, heart attacks, or strokes in bleeding patients receiving tranexamic acid at standard doses of 2 grams per day or less.
Seizures are a dose-dependent risk. At standard doses, there was no statistically significant increase. But patients receiving more than 2 grams per day had roughly three times the risk of seizures compared to those who did not receive the drug. This is why high doses are generally avoided.
Milder side effects can include nausea, diarrhea, and nasal congestion with oral forms. These tend to be manageable and resolve after stopping the medication.
Who Should Not Take Antifibrinolytics
Tranexamic acid is contraindicated in three specific situations. Patients with active clotting inside blood vessels (a condition called active intravascular clotting, such as disseminated intravascular coagulation) should not receive it, because stabilizing clots in that scenario can worsen organ damage. It is also contraindicated in subarachnoid hemorrhage, a type of bleeding around the brain, because it has been linked to brain swelling and stroke in those patients. Severe allergic reactions to the drug rule out future use as well.
Because these drugs are cleared almost entirely by the kidneys, people with severe kidney impairment need careful dose adjustments to avoid the drug accumulating to unsafe levels. Anyone with a personal history of blood clots, including deep vein thrombosis or pulmonary embolism, requires a careful risk-benefit discussion before starting therapy.